ClinVar Miner

Submissions for variant NM_000535.7(PMS2):c.1261C>T (p.Arg421Ter) (rs587778617)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000076804 SCV000108286 pathogenic Lynch syndrome 2013-09-05 reviewed by expert panel research Coding sequence variation resulting in a stop codon
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000076804 SCV000271438 pathogenic Lynch syndrome 2016-03-03 criteria provided, single submitter clinical testing The p.Arg421X variant in PMS2 has been reported in one carrier with unspecified phenotype (Suerink 2015), and was absent from large population studies. This non sense variant leads to a premature termination codon at position 421, which is p redicted to lead to a truncated or absent protein. Heterozygous loss of function of the PMS2 gene is an established disease mechanism in Lynch syndrome. In summ ary, this variant meets our criteria to be classified as pathogenic for Lynch sy ndrome in an autosomal dominant manner based upon the predicted impact to the pr otein.
Ambry Genetics RCV000223405 SCV000276002 pathogenic Hereditary cancer-predisposing syndrome 2019-03-14 criteria provided, single submitter clinical testing Alterations resulting in premature truncation (e.g.reading frame shift, nonsense)
GeneDx RCV000219846 SCV000279393 pathogenic not provided 2018-11-20 criteria provided, single submitter clinical testing This pathogenic variant is denoted PMS2 c.1261C>T at the cDNA level and p.Arg421Ter (R421X) at the protein level. The substitution creates a nonsense variant, which changes an Arginine to a premature stop codon (CGA>TGA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant has been observed in at least two individuals with suspected Lynch Syndrome (Vaughn 2013, Suerink 2015). The International Society for Gastrointestinal Hereditary Tumours Incorporated (InSiGHT) classifies this variant as pathogenic (Thompson 2014). Based on current information, we consider this variant to be pathogenic.
Invitae RCV000627692 SCV000285057 pathogenic Hereditary nonpolyposis colorectal neoplasms 2019-11-16 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg421*) in the PMS2 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individuals with colorectal cancer and/or suspected Lynch syndrome (PMID: 23012243, 26110232). ClinVar contains an entry for this variant (Variation ID: 91299). Loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816). For these reasons, this variant has been classified as Pathogenic.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000076804 SCV000592931 pathogenic Lynch syndrome 2015-01-13 criteria provided, single submitter clinical testing
GeneKor MSA RCV000223405 SCV000821766 pathogenic Hereditary cancer-predisposing syndrome 2020-01-01 criteria provided, single submitter clinical testing This is a point mutation replacing one nucleotide in the position 1261 of the PMS2 gene, leading in the replacement of Arginine with a termination stop codon in the position 421 of the PMS2 protein. The resulting protein is truncated and non functional. This particular variant has been described in international literature in families with colorectal cancer and/or Lynch syndrome (PMID: 23012243, PMID: 26110232). The mutation database ClinVar contains an entry for this variant (Variation ID: 91299).
Color RCV000223405 SCV001347955 pathogenic Hereditary cancer-predisposing syndrome 2020-01-15 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV001255553 SCV001432025 pathogenic Hereditary nonpolyposis colon cancer 2020-08-25 criteria provided, single submitter clinical testing Variant summary: PMS2 c.1261C>T (p.Arg421X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251060 control chromosomes (gnomAD). c.1261C>T has been reported in the literature in individuals with suspected Hereditary Nonpolyposis Colorectal Cancer (e.g. Vaughn_2013, Suerink_2016). It has also been reported by different studies in a number of individuals affected with breast cancer (e.g. Roberts_2018, Tsaousis_2019, Fostira_2020), with one of the studies concluding that pathogenic variants in the PMS2 gene are associated with an increased risk for breast cancer following retrospective review of patient data (Roberts_2018). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight ClinVar submitters (evaluation after 2014) cite the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
ITMI RCV000121843 SCV000086041 not provided not specified 2013-09-19 no assertion provided reference population
Bioscientia Institut fuer Medizinische Diagnostik GmbH,Sonic Healthcare RCV000786880 SCV000925779 likely pathogenic Hereditary nonpolyposis colorectal cancer type 4 2018-09-27 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.